Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers

Surgical Infections

Volumn 17, Issue 4, 2016, Pages 443-447

  Sader, Helio S ^a   Farrell, David J ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; DRUG POTENCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN STRUCTURE; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; SURGICAL SKIN AND SKIN STRUCTURE INFECTION; CLINICAL TRIAL; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84979680975     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2015.209     Document Type: Article

References (20)

1. Kirkland KB, Briggs JP, Trivette SL, et al. The impact of surgical-site infections in the 1990s: Attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999;20:725-730
2. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobialresistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34:1-14
3. Weigelt JA, Lipsky BA, Tabak YP, et al. Surgical site infections: Causative pathogens and associated outcomes. Am J Infect Control 2010;38:112-120
4. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195-283
5. Crawford T, Rodvold KA, Solomkin JS. Vancomycin for surgical prophylaxis? Clin Infect Dis 2012;54:1474-1479
6. Sader HS, Flamm RK, Streit J, et al. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: Results from five years of the AWARE surveillance program. Antimicrob Agents Chemother 2015; 59:2458-2461
7. TEFLARO (Ceftaroline fosamil) injection for intravenous (IV) use. 2012
8. CLSI. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-tenth edition. Wayne, PA: Clinical and Laboratory Standards Institute, 2015
9. CLSI. M100-S25. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2015
10. Tygacil Philadelphia, PA: Wyeth Pharmaceuticals, 2014
11. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0, January 2015. European Committee on Antimicrobial Susceptibility Testing, 2015
12. Sader HS, Farrell DJ,Mendes RE, et al. Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. DiagnMicrobiol Infect Dis 2015;82:78-84
13. Patel M, Kumar RA, Stamm AM, et al. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol 2007;45:3431-3433
14. Manian FA, Griesnauer S. Community-associatedmethicillinresistant Staphylococcus aureus (MRSA) is replacing traditional health care-associated MRSA strains in surgical-site infections among inpatients. Clin Infect Dis 2008;47:434-435
15. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg 2007;83:1569-1576
16. Bolon MK, Morlote M, Weber SG, et al. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: A meta-analysis. Clin Infect Dis 2004;38:1357-1363
17. Bull AL, Worth LJ, Richards MJ. Impact of vancomycin surgical antibiotic prophylaxis on the development of methicillin-sensitive Staphylococcus aureus surgical site infections: Report from Australian Surveillance Data (VICNISS). Ann Surg 2012;256:1089-1092
18. Sabath LD, Wilcox C, Garner C, Finland M. In vitro activity of cefazolin against recent clinical bacterial isolates. J Infect Dis 1973;128:S320-S326
19. Mendes RE, Tsakris A, Sader HS, et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 2012;67:1321-1324
20. Alm RA, McLaughlin RE, Kos VN, et al. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective. J Antimicrob Chemother 2014;69:2065-2075